PURPOSE OF REVIEW: To give an overview of recently published articles about the management of vasculo-Behcet's with particular emphasis on anticoagulation. RECENT FINDINGS: Biologic agents are emerging as a potential therapeutic option in refractory vasculo-Behcet with a good safety profile. Evidence further shows that following nonpulmonary aneurysm repair, there is a reduced risk of recurrent aneurysmal formation at the operative site in patients treated with immunosuppressants in addition to their surgery, than those undergoing surgical intervention alone. SUMMARY: Behcet disease patients are at risk of developing multiple vascular complications including thrombosis and aneurysms. Treatment should focus on reducing inflammation; and the role of anticoagulation is still debatable.
PURPOSE OF REVIEW: To give an overview of recently published articles about the management of vasculo-Behcet's with particular emphasis on anticoagulation. RECENT FINDINGS: Biologic agents are emerging as a potential therapeutic option in refractory vasculo-Behcet with a good safety profile. Evidence further shows that following nonpulmonary aneurysm repair, there is a reduced risk of recurrent aneurysmal formation at the operative site in patients treated with immunosuppressants in addition to their surgery, than those undergoing surgical intervention alone. SUMMARY:Behcet diseasepatients are at risk of developing multiple vascular complications including thrombosis and aneurysms. Treatment should focus on reducing inflammation; and the role of anticoagulation is still debatable.
Authors: Bernardo Baptista; Natália Marto; João Galaz Tavares; Alexandra Bayão Horta; Diogo Cunha E Sá; Gonçalo Gerardo; Manuela Mafra Journal: Eur J Case Rep Intern Med Date: 2019-03-01